Open Demat
Be a Partner
Samadhan
Install App
Install App

24715

544222

AKUMS

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

AKUMS DRUGS AND PHARMA L Share Price Update

As of the latest trading session, AKUMS DRUGS AND PHARMA L is trading at ₹534.3, up by ₹3.00 or 0.56% from its previous close. The stock has moved between ₹529.95 and ₹537.80 today. Over the past year, the stock has delivered a return of 1.29%. In the last month, it has returned 12.00%.

AKUMS DRUGS AND PHARMA L performance

Today’s low Today’s high
₹ 529.95 ₹ 537.80
₹ 530.00
52 week low 52 week high
₹ 409.30 ₹ 622.95
₹ 530.00
Open Price ₹ 530.00
Prev. Close ₹ 531.30
Volume (Shares) 95.00
Total traded value ₹ .50
Upper Circuit ₹ 584.40
Lower Circuit ₹ 478.20
info

Investment Returns

Over 1 Month 12.00% Over 3 Months 23.91% Over 6 Months 14.03% Over 1 Year 1.29%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

AKUMS DRUGS AND PHARMA L fundamentals


  • Market cap (Cr) 8,362.30
  • P/E Ratio (TTM) 67.46
  • Beta 1.04
  • Book Value / share 150.81
  • Return on equity 13.15%
  • EPS (TTM) 8.06
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 28.11
info icon alternate text
  • Market cap (Cr) 8,341.90
  • P/E Ratio (TTM) 67.46
  • Beta 1.05
  • Book Value / share 150.81
  • Return on equity 13.15%
  • EPS (TTM) 8.06
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 28.11
info icon alternate text

AKUMS DRUGS AND PHARMA L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 368.61
Operating Expense 358.53
Net Profit 28.11
Net Profit Margin (%) 7.62
Earnings Per Share (EPS) 1.84
EBITDA 50.48
Effective Tax Rate (%) 21.60
Particulars SEP 2025 (Values in Cr)
Revenue 309.32
Operating Expense 305.19
Net Profit 23.46
Net Profit Margin (%) 7.58
Earnings Per Share (EPS) 1.53
EBITDA 43.97
Effective Tax Rate (%) 24.80
Particulars JUN 2025 (Values in Cr)
Revenue 332.44
Operating Expense 301.49
Net Profit 44.87
Net Profit Margin (%) 13.49
Earnings Per Share (EPS) 2.93
EBITDA 72.67
Effective Tax Rate (%) 24.60
Particulars MAR 2025 (Values in Cr)
Revenue 328.75
Operating Expense 323.75
Net Profit 27.59
Net Profit Margin (%) 8.39
Earnings Per Share (EPS) 1.80
EBITDA 49.78
Effective Tax Rate (%) 25.55
Particulars DEC 2024 (Values in Cr)
Revenue 337.41
Operating Expense 316.35
Net Profit 41.17
Net Profit Margin (%) 12.20
Earnings Per Share (EPS) 2.69
EBITDA 67.86
Effective Tax Rate (%) 24.99
Particulars MAR 2025 (Values in Cr)
Revenue 1311.78
Operating Expense 1228.13
Net Profit 161.00
Net Profit Margin (%) 12.27
Earnings Per Share (EPS) 10.76
EBITDA 262.70
Effective Tax Rate (%) 22.53
Particulars MAR 2024 (Values in Cr)
Revenue 1444.12
Operating Expense 1621.78
Net Profit -165.45
Net Profit Margin (%) -11.45
Earnings Per Share (EPS) -11.56
EBITDA -51.93
Effective Tax Rate (%) -60.74
Particulars MAR 2023 (Values in Cr)
Revenue 1286.83
Operating Expense 1088.13
Net Profit 125.43
Net Profit Margin (%) 9.74
Earnings Per Share (EPS) 8.77
EBITDA 193.50
Effective Tax Rate (%) 16.55
Particulars MAR 2022 (Values in Cr)
Revenue 1162.06
Operating Expense 1555.51
Net Profit -381.78
Net Profit Margin (%) -32.85
Earnings Per Share (EPS) -53.33
EBITDA -303.57
Effective Tax Rate (%) -13.97
Particulars MAR 2021 (Values in Cr)
Revenue 837.44
Operating Expense 837.66
Net Profit -145.43
Net Profit Margin (%) -17.36
Earnings Per Share (EPS) -20.33
EBITDA -168.28
Effective Tax Rate (%) 25.49
Particulars MAR 2025 (Values in Cr)
Book Value / Share 199.01
ROE % 18.30
ROCE % 12.86
Total Debt to Total Equity 0.17
EBITDA Margin 12.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 49.59
ROE % -2.22
ROCE % 1.24
Total Debt to Total Equity 0.83
EBITDA Margin 3.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 50.13
ROE % 19.46
ROCE % 11.73
Total Debt to Total Equity 0.76
EBITDA Margin 10.32
Particulars MAR 2022 (Values in Cr)
Book Value / Share 86.95
ROE % -33.30
ROCE % -9.43
Total Debt to Total Equity 0.33
EBITDA Margin -2.23
Particulars MAR 2021 (Values in Cr)
Book Value / Share 6801.28
ROE % 15.36
ROCE % 11.61
Total Debt to Total Equity 0.19
EBITDA Margin 9.14
Particulars MAR 2025 (Values in Cr)
Book Value / Share 150.57
ROE % 13.15
ROCE % 10.70
Total Debt to Total Equity 0.13
EBITDA Margin 20.03
Particulars MAR 2024 (Values in Cr)
Book Value / Share 10.06
ROE % -69.16
ROCE % -3.92
Total Debt to Total Equity 0.91
EBITDA Margin -2.23
Particulars MAR 2023 (Values in Cr)
Book Value / Share 21.77
ROE % 92.77
ROCE % 21.17
Total Debt to Total Equity 0.57
EBITDA Margin 26.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share 25.94
ROE % -101.46
ROCE % -25.83
Total Debt to Total Equity 0.22
EBITDA Margin -26.12
Particulars MAR 2021 (Values in Cr)
Book Value / Share 4358.55
ROE % 17.25
ROCE % 4.52
Total Debt to Total Equity 0.05
EBITDA Margin 9.70
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 576.45
Total Assets 4113.44
Total Liabilities 4113.44
Total Equity 3063.61
Share Outstanding 15
Price to Book Ratio 3.15
Return on Assets (%) 8.22
Return on Capital (%) 10.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 277.05
Total Assets 3516.36
Total Liabilities 3516.36
Total Equity 720.48
Share Outstanding 14
Price to Book Ratio 0.00
Return on Assets (%) -0.11
Return on Capital (%) -0.33
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 149.98
Total Assets 3266.52
Total Liabilities 3266.52
Total Equity 723.37
Share Outstanding 14
Price to Book Ratio 0.00
Return on Assets (%) 2.90
Return on Capital (%) 7.53
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 102.84
Total Assets 3069.04
Total Liabilities 3069.04
Total Equity 625.17
Share Outstanding 7
Price to Book Ratio 0.00
Return on Assets (%) -8.22
Return on Capital (%) -25.69
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 67.86
Total Assets 2166.87
Total Liabilities 2166.87
Total Equity 887.13
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 5.66
Return on Capital (%) 12.47
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 356.11
Total Assets 2684.91
Total Liabilities 2684.91
Total Equity 2305.24
Share Outstanding 15
Price to Book Ratio 3.15
Return on Assets (%) 5.99
Return on Capital (%) 6.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 73.31
Total Assets 2095.42
Total Liabilities 2095.42
Total Equity 143.87
Share Outstanding 14
Price to Book Ratio 0.00
Return on Assets (%) -7.89
Return on Capital (%) -44.7
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.84
Total Assets 1894.20
Total Liabilities 1894.20
Total Equity 311.50
Share Outstanding 14
Price to Book Ratio 0.00
Return on Assets (%) 6.62
Return on Capital (%) 27.44
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.73
Total Assets 1813.94
Total Liabilities 1813.94
Total Equity 185.53
Share Outstanding 7
Price to Book Ratio 0.00
Return on Assets (%) -21.04
Return on Capital (%) -124.1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.99
Total Assets 1298.35
Total Liabilities 1298.35
Total Equity 567.04
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) -11.20
Return on Capital (%) -24.66
Particulars MAR 2025 (Values in Cr)
Net Income 345.25
Cash from Operations 546.43
Cash from Investing -547.84
Cash from Financing 72.78
Net change in Cash -9.85
Free Cash Flow 818.74
Particulars MAR 2024 (Values in Cr)
Net Income -45.27
Cash from Operations 560.67
Cash from Investing -330.41
Cash from Financing -108.02
Net change in Cash 59.82
Free Cash Flow 872.08
Particulars MAR 2023 (Values in Cr)
Net Income 150.29
Cash from Operations 273.69
Cash from Investing -304.70
Cash from Financing 124.54
Net change in Cash -3.53
Free Cash Flow 602.48
Particulars MAR 2022 (Values in Cr)
Net Income -193.19
Cash from Operations 86.67
Cash from Investing -234.82
Cash from Financing 236.04
Net change in Cash 33.07
Free Cash Flow 344.25
Particulars MAR 2021 (Values in Cr)
Net Income 172.26
Cash from Operations 176.16
Cash from Investing -109.38
Cash from Financing -91.46
Net change in Cash -70.23
Free Cash Flow 258.97
Particulars MAR 2025 (Values in Cr)
Net Income 207.83
Cash from Operations 139.87
Cash from Investing -458.84
Cash from Financing 375.37
Net change in Cash 7.53
Free Cash Flow 235.48
Particulars MAR 2024 (Values in Cr)
Net Income -102.93
Cash from Operations 284.19
Cash from Investing -165.44
Cash from Financing -20.74
Net change in Cash 61.72
Free Cash Flow 356.05
Particulars MAR 2023 (Values in Cr)
Net Income 150.31
Cash from Operations 35.57
Cash from Investing -202.16
Cash from Financing 89.90
Net change in Cash -18.25
Free Cash Flow 151.83
Particulars MAR 2022 (Values in Cr)
Net Income -334.97
Cash from Operations 235.50
Cash from Investing -297.95
Cash from Financing 94.98
Net change in Cash 25.34
Free Cash Flow 265.79
Particulars MAR 2021 (Values in Cr)
Net Income -195.19
Cash from Operations -242.91
Cash from Investing -99.96
Cash from Financing 2.59
Net change in Cash -41.78
Free Cash Flow -209.83
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.76 15.05 1.80 266.38 23.12 40.44
BLISS GVS PHARMA LTD 273.70 26.17 2.55 2895.44 105.05 277.80
CIPLA LTD 1317.15 22.38 3.23 106397.09 1165.55 1672.20
FERMENTA BIOTECH LIMITED 314.25 10.45 2.36 924.87 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.76 33.42 4.84 266.38 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 581.15 29.06 4.91 1680.14 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8576.10 103.07 26.83 21440.25 7630.00 10653.05
BLISS GVS PHARMA LTD 273.70 37.29 2.62 2895.44 105.05 277.80

AKUMS DRUGS AND PHARMA L shareholding pattern

Holding
9.01%
75.26%
1.37%
14.34%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

AKUMS DRUGS AND PHARMA L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
531.30 0.00 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 529.20
  • 26 Days 511.20
  • 10 Days 526.90
  • 50 Days 495.10
  • 12 Days 525.00
  • 100 Days 480.20
  • 20 Days 516.70
  • 200 Days 494.80
525.97 PIVOT
First Support 519.23 First Resistance 538.03 Second Support 507.17 Second Resistance 544.77 Third Support 500.43 Third Resistance 556.83
RSI 56.71 ADX 37.12 MACD 13.75 Williams % R -37.25 Commodity Channel Index (CCI) 39.59
Date 2026-04-27 Week 72842.00 Same Day 82050.00 Month 108474.00
1 Year 1.05 3 Year 1.21
Over 1 Month
12.00% down
Over 1 Year
1.29% down
Over 3 Months
23.91% down
Over 3 Years
0.00% down
Over 6 Months
14.03% down
Over 5 Years
0.00% down

AKUMS DRUGS AND PHARMA L Corporate Actions

Top Gainers

up-arrow (%)

Top Losers

up-arrow (%)

AKUMS DRUGS AND PHARMA L Share Price

Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.

Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Some of manufacturing units have been accredited by various global regulatory agencies such as the European Good Manufacturing Practice, the World Health Organization Good Manufacturing Practice and the United States National Sanitation Foundation. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as anti-infective, respiratory and diabetes.

In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones ; dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.

In 2011, it innovated bi-layered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established R&D Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015.

In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private Limited

Following a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an R&D centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs.

The Company launched an IPO by issuing 27,368,151 equity shares of Rs 2 each by raising funds aggregating to Rs 1857 Crore comprising a fresh issue of 10,037,716 equity shares aggregating to Rs 680 Crore and offer for sale of 17,330,435 equity shares aggregating to Rs 1177 Crore in August, 2024.

Akums Healthcare UK Ltd. was incorporated as a foreign wholly owned subsidiary of the Company on 18th March, 2025. The new state-ofthe-art facilities at Kotdwar and Haridwar, focusing on Penem anti infectives and general injectables, have enhanced the manufacturing capacity in FY 2025.

Parent organization Indian Private
NSE symbol AKUMS
Founded 2004
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Sandeep Jain Managing Director
Sanjeev Jain Managing Director
Matangi Gowrishankar Independent Director
Dharamvir Malik Company Sec. & Compli. Officer
Kewal Kundanlal Handa Independent Director
Sanjay Sinha Whole-time Director
Sunil Kumar Thakur Non Executive Director
Satwinder Singh Independent Director
Anil Kumar Arvindlal Amin Independent Director
Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
0.53%
1742.8 9.30
down-arrow
similar-logo DIVISLAB
0.10%
6483.5 6.50
down-arrow
similar-logo TORNTPHARM
0.59%
4245 25.20
down-arrow
similar-logo DRREDDY
0.67%
1343.5 9.00
down-arrow
similar-logo CIPLA
0.16%
1319.4 2.20
down-arrow
similar-logo LUPIN
-1.78%
2283.1 -41.39
down-arrow
similar-logo ZYDUSLIFE
-2.78%
913.45 -26.20
down-arrow
similar-logo MANKIND
-0.44%
2258.6 -10.09
down-arrow
similar-logo AUROPHARMA
0.59%
1425.1 8.40
down-arrow
similar-logo GLENMARK
3.49%
2406.4 81.29
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

Akums Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 534.30 & for BSE ₹ 534.00 as on Apr 28 2026 10:29 AM.

What is the Market Cap of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

The market cap of Akums Drugs & Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Apr 28 2026 10:29 AM.

What is the 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Akums Drugs & Pharmaceuticals Ltd for NSE is ₹ 622.95 and ₹ 409.30 and for BSE is ₹ 620.00 and ₹ 410.10.

What is 1 year return for Akums Drugs & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 1.29%.

What is the P/E Ratio of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 10:29 AM the price-to-earnings (PE) ratio for Akums Drugs & Pharmaceuticals Ltd share is 67.46.

What is the PB ratio of Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Apr 28 2026 10:29 AM, the price-to-book (PB) ratio for Akums Drugs & Pharmaceuticals Ltd share is 150.81.

How to Buy Akums Drugs & Pharmaceuticals Ltd Share?

Answer Field

You can trade in Akums Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Akums Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Akums Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Akums Drugs & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Products

arrow

Calculators

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email for any investor grievances or write to us for DP related matters.

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email | Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.